Effects of L-carnitine on genetic, inflammation and antioxidant factors in Nonalcoholic Steatohepatitis patients.

Study of the Serum levels of miRNA-16, miRNA-21, miRNA-217 and effects of L-carnitine on their levels , TNF-a , TGF-ß cytokines, Malondialdehyde and CRP in Nonalcoholic Steatohepatitis (NASH) patients under weight loss regimen

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201212052602N8

Enrollment

Registered

2013-02-04

Start date

2013-01-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic steatohepatitis. Nonalcoholic steatohepatitis( NASH)

Interventions

Intervention 1: . Intervention group receives 2000 mg of L-carnitine as 2 vials,before the meals, for 12 weeks. Intervention 2: Control group receives 2000 mg of Placebo as 2 vials,before the meals, f

Treatment - Drugs

. Intervention group receives 2000 mg of L-carnitine as 2 vials,before the meals, for 12 weeks.

Control group receives 2000 mg of Placebo as 2 vials,before the meals, for 12 weeks.

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria : age between 18-65 years; BMI=25 kg/m2, under weight loss regimen ; ALT=1.5 fold normal; Sonography showing Nonalcoholic Steatohepatitis ; Exclusion criteria: not willing toCollaborate; viral hepatitis; taking Insulin; blood lipid-lowering agents;Antiinflammatory drugs(stroid and non stroid) and antioxidant supplements; smoking cigarettes.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
TNF-a. Timepoint: At first of the study and 12th week. Method of measurement: labratory kit.;TGF-ß. Timepoint: At first of the study and 12th week. Method of measurement: Sandwich Elisa.;Malondialdehide. Timepoint: At first of the study and 12th week. Method of measurement: Sandwich Elisa.;CRP. Timepoint: At first of the study and 12th week. Method of measurement: labratory kit.;MiRNA-16. Timepoint: At first of the study and 12th week. Method of measurement: RT-PCR.;MiRNA-21. Timepoint: At first of the study and 12th week. Method of measurement: RT-PCR.;MiRNA-217. Timepoint: At first of the study and 12th week. Method of measurement: RT-PCR.	—

Measure

Time frame

TNF-a. Timepoint: At first of the study and 12th week. Method of measurement: labratory kit.;TGF-ß. Timepoint: At first of the study and 12th week. Method of measurement: Sandwich Elisa.;Malondialdehide. Timepoint: At first of the study and 12th week. Method of measurement: Sandwich Elisa.;CRP. Timepoint: At first of the study and 12th week. Method of measurement: labratory kit.;MiRNA-16. Timepoint: At first of the study and 12th week. Method of measurement: RT-PCR.;MiRNA-21. Timepoint: At first of the study and 12th week. Method of measurement: RT-PCR.;MiRNA-217. Timepoint: At first of the study and 12th week. Method of measurement: RT-PCR.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Shirin Amiri Moghaddam

School of public Health,Tehran University of Medical Sciences

amiri_shirin14@yahoo.com+98 21 8877 9118

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026